BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28210267)

  • 1. MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer.
    Chan LW; Wang F; Meng F; Wang L; Wong SC; Au JS; Yang S; Cho WC
    Front Genet; 2017; 8():8. PubMed ID: 28210267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
    Moreno P; Lara-Chica M; Soler-Torronteras R; Caro T; Medina M; Álvarez A; Salvatierra Á; Muñoz E; Calzado MA
    PLoS One; 2015; 10(11):e0143376. PubMed ID: 26580787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.
    Meng F; Wang F; Wang L; Wong SC; Cho WC; Chan LW
    Front Genet; 2016; 7():197. PubMed ID: 27895663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells
    Chiu HY; Chiang CM; Yeh SP; Jong DS; Wu LS; Liu HC; Chiu CH
    Oncol Lett; 2020 Nov; 20(5):206. PubMed ID: 32963612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
    Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1.
    Chen J; Cui JD; Guo XT; Cao X; Li Q
    Cancer Med; 2018 Apr; 7(4):1394-1403. PubMed ID: 29493886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
    Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
    Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
    Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells.
    Bach DH; Kim D; Bae SY; Kim WK; Hong JY; Lee HJ; Rajasekaran N; Kwon S; Fan Y; Luu TT; Shin YK; Lee J; Lee SK
    Mol Ther Nucleic Acids; 2018 Jun; 11():455-467. PubMed ID: 29858080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
    Li B; Ren S; Li X; Wang Y; Garfield D; Zhou S; Chen X; Su C; Chen M; Kuang P; Gao G; He Y; Fan L; Fei K; Zhou C; Schmit-Bindert G
    Lung Cancer; 2014 Feb; 83(2):146-53. PubMed ID: 24331411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of miR-23a increases the sensitivity of lung cancer stem cells to erlotinib through PTEN/PI3K/Akt pathway.
    Han Z; Zhou X; Li S; Qin Y; Chen Y; Liu H
    Oncol Rep; 2017 Nov; 38(5):3064-3070. PubMed ID: 28901474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Siah2 Is Associated With Poor Prognosis in Patients With Epithelial Ovarian Carcinoma.
    Gao Y; Liu Y; Meng F; Shang P; Wang S; Zhang Y; Sun Y; Wang Y; Wang J; Chen X
    Int J Gynecol Cancer; 2016 Jan; 26(1):114-9. PubMed ID: 26512788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
    Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
    Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
    Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.